2022 SHS| Professor Fu Jianhong: Frontier progress in the diagnosis and treatment of blood disease infection and severe disease

Patients with blood diseases are at high risk of infection, often immunocompromised due to disease or treatment, complicated by infection or even severe disease
.
Hematological infection is closely related to the diagnosis and treatment outcomes of severe disease and the prognosis of patients with hematological diseases, so the clinical diagnosis and treatment of hematological infections and severe diseases have attracted much attention
.

On October 8, 2022, the "2022 Suzhou Hematology Summit" was held in Suzhou, inviting well-known hematology experts at home and abroad to conduct in-depth discussions
on the new progress in the diagnosis and treatment of blood diseases, precision medicine and leukemia, and the construction of big data platform.
On this occasion, Yimaitong specially invited Professor Fu Jianhong of the First Affiliated Hospital of Soochow University to be interviewed to share the progress
of clinical diagnosis and treatment of blood disease infection and severe disease.

Medical Pulse: Patients with blood diseases are immunocompromised due to disease causes or treatment drugs, and are often co-infected
during the diagnosis and treatment of diseases.
There are many pathogens in clinical infection, and accurate diagnosis of pathogens is very important for precision anti-infection treatment, can you talk about the current status and progress of infectious pathogen diagnosis technology?

Patients with hematological disorders, especially those with hematological malignancies, will experience mucosal damage or severe myelosuppression due to induction chemotherapy or hematopoietic stem cell transplantation, resulting in severe and prolonged agranulocytosis and concurrent infection
.
Once the infection has occurred, it is important to identify the causative agent
.
However, for immunodeficient hosts, the pathogen detection rate is low by routine microbiological examination and culture techniques, and some special pathogens cannot be detected
by routine detection techniques.
In recent years, technologies such as infection markers, molecular biology, microbial metagenes and pathogenic sequencing have emerged, which have significantly improved the positive rate of pathogen detection and improved the level of
clinical anti-infection diagnosis and treatment.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a common treatment for blood diseases, and allo-HSCT is often complicated with cytomegalovirus (CMV) infection, which seriously affects the prognosis
of patients.
This year, China released the first expert consensus on CMV infection management - "Chinese Expert Consensus on the Management of Giant Cell Infection in Allogeneic Hematopoietic Stem Cell Transplantation Patients (2022 Edition)", can you talk about the diagnosis and treatment experience of allo-HSCT combined with CMV infection in clinical diagnosis and treatment for many years?

Hematopoietic stem cell transplantation is a characteristic diagnosis and treatment technology of the hematology department of our hospital, with more than 800 transplant cases every year
.
Patients with serious infectious complications after hematopoietic stem cell transplantation, such as CMV infection and respiratory failure, will be referred to a hematology specialist for ICU treatment
.
Combined with years of experience in the diagnosis and treatment of hematology specialist ICUs and the newly issued "Chinese Expert Consensus on the Management of Giant Cell Infection in Allogeneic Hematopoietic Stem Cell Transplantation Patients (2022 Edition)", CMV prophylaxis or preemptive treatment can significantly improve the prognosis
of high-risk patients, such as haploid, patients with ATG pretreatment or severe graft-versus-host disease (GVHD).

Medical Pulse Communication: Blood diseases often develop into severe diseases due to diseases or comorbidities, and early identification and treatment is the key to
critical diagnosis and treatment.
Can you please talk about the progress in the diagnosis and treatment of severe blood disease based on years of clinical experience?

In the treatment of malignant hematological diseases, life-threatening emergencies can
occur due to disease invasion or metastasis.
For the management of acute and critical illness, early diagnosis and timely intervention are very important
.
The 2022 Suzhou Blood Summit set up a branch venue for severe blood disease and infection, inviting experts from the diagnosis and treatment of blood infection and ICU to discuss together, and the experts agreed that a multidisciplinary diagnosis and treatment team or hematology specialist ICU is very necessary
to improve the prognosis of patients with acute and severe blood diseases.

Prof.
Jianhong Fu

• The First Affiliated Hospital of Soochow University, Deputy Chief Physician, Doctor of Medicine

• In 2003, he graduated from West China Medical Center of Sichuan University and entered the ICU of the First Affiliated Hospital of Soochow University, and was transferred to the Department of Hematology in 2018, specializing in the treatment of critical blood diseases

• 2007.
  8-2008.
  2 Specialized training in MICU, Peking Union Medical College Hospital

• In 2009, he participated in the designated ICU treatment of severe patients with H1N1 influenza A in Suzhou

• In 2014, he participated in the treatment of critically ill patients with avian influenza, and in the same year, he was praised by the Jiangsu Provincial Health and Family Planning Commission for his outstanding performance in the rescue of the "8.
  2" wounded in Kunshan

• In 2016, she was supported by a Takeda Scholarship to study at the Affiliated Hospital of Tokyo Women's Medical University as a visiting scholar

• In February 2020, he went to Suzhou Fifth People's Hospital to participate in the treatment of COVID-19 patients

• In 2020, he was named one of the "Top Ten Doctors" of the First Affiliated Hospital of Suzhou University

• In the past three years, he has participated in the publication of 5 SCI papers, with a cumulative impact factor of 20 points